Open Your Free Demat Account
Enjoy low brokerage on delivery trades
Sai Parenteral’s Ltd. is a pharmaceutical formulations company engaged in research, development, and manufacturing activities. The Sai Parenteral’s Limited IPO is scheduled to open on March 24, 2026, and close on March 27, 2026. The issue comprises 1,04,28,288 shares with a price band of ₹372 to ₹392 per share and is proposed to be listed on the stock exchanges, subject to applicable approvals. The IPO includes provisions for different investor categories and outlines the company’s participation in both domestic and international pharmaceutical markets.
Sai Parenteral’s Ltd. operates in the pharmaceutical formulations segment with activities across research, development, and manufacturing. The company’s operations are divided into branded generic formulations and contract development and manufacturing organisation (CDMO) services, catering to domestic and international markets. Its product portfolio includes formulations across therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, dermatology, and vitamins, minerals, and supplements. These products are available in multiple dosage forms, including injectables, tablets, capsules, liquid orals, and ointments, indicating a diversified product presence. The company supplies its products to government institutions, pharmaceutical companies, hospitals, and distribution networks. It has also entered export markets following the acquisition of internationally accredited facilities, enabling supply to regulated and semi-regulated regions. Its manufacturing network includes multiple facilities with GMP and WHO-GMP certifications, supporting its operational capabilities.
To apply for the Sai Parenteral’s IPO, investors can use the ASBA (Application Supported by Blocked Amount) facility through their bank account or apply via UPI-enabled platforms offered by stockbrokers. The process involves selecting the IPO, entering bid details such as quantity and price within the specified band, and authorising the payment request. The application amount remains blocked in the bank account until allotment is finalised, in accordance with regulatory processes. Alternatively, investors may apply through online trading platforms by logging into their account, selecting the IPO section, and submitting the application using UPI authentication. It is necessary to ensure that the demat account details, PAN, and bank information are correctly updated before placing the bid. The allotment status can be checked after the basis of allotment is finalised, and shares, if allotted, are credited to the demat account as per the applicable timelines.
For more details, visit the Sai Parenterals Limited IPO page.
Details | Information |
IPO Date | Mar 24, 2026 to Mar 27, 2026 |
Issue Size | 1,04,28,288 shares (agg. up to ₹409 Cr) |
Price Band | ₹372 to ₹392 per share |
Lot Size | 38 shares |
Listing At | BSE NSE |
Capacity expansion and upgradation of manufacturing facilities
Establishment of a new R&D centre
Repayment / prepayment of certain outstanding borrowings
Working capital requirements
Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenteral’s Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia)
General corporate purposes
Event | Date |
IPO Open Date | Tue, Mar 24, 2026 |
IPO Close Date | Fri, Mar 27, 2026 |
Tentative Allotment | Mon, Mar 30, 2026 |
Initiation of Refunds | Wed, Apr 1, 2026 |
Credit of Shares to Demat | Wed, Apr 1, 2026 |
Tentative Listing Date | Thu, Apr 2, 2026 |
Cut-off time for UPI mandate confirmation | 5 PM on Fri, Mar 27, 2026 |
₹372 to ₹392 per share
Application | Lots | Shares | Amount |
Retail (Min) | 1 | 38 | ₹14,896 |
Retail (Max) | 13 | 494 | ₹1,93,648 |
S-HNI (Min) | 14 | 532 | ₹2,08,544 |
S-HNI (Max) | 67 | 2,546 | ₹9,98,032 |
B-HNI (Min) | 68 | 2,584 | ₹10,12,928 |
The Sai Parenteral’s Limited IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:
Access your trading account using the broker's app or website.
Go to the IPO section to view active IPO listings.
Locate Sai Parenteral’s Limited IPO in the list of available IPOs and click the ‘Apply’ button.
Specify the number of shares (lot size: 38 shares) within the price band of ₹372 to ₹392 per share.
Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.
Review your application details and confirm the UPI mandate before 5 PM on the last application day.
Submit the application and monitor the allotment status to check if shares have been allocated to you.
The allocation of shares in the Sai Parenteral’s IPO is structured across investor categories in line with applicable regulatory requirements. The issue provides defined reservations for qualified institutional buyers, non-institutional investors, and retail individual investors, with each category allotted a specified proportion of the net issue. This allocation framework outlines how the shares offered are distributed among different classes of investors.
Investor Category | Shares Offered |
Anchor Investors | 31,28,486 (30.00%) |
Non-Institutional Investor | 15,64,243 (15.00%) |
Qualified Institutional Buyers | 20,85,658 (20.00%) |
Retail Individual Investor | 36,49,901 (35.00%) |
Total Shares Offered | 1,04,28,288 (100.00%) |
This reservation structure reflects the categorisation and allocation approach disclosed for the issue, indicating the proportion of shares available to each investor segment.
Total Assets: Grew from ₹133.96 crore in FY23 to ₹376.24 crore as of Sept 2025.
Total income: Recorded at ₹89.43 crore in Sept 2025, as compared to ₹97.03 crore in FY23.
Profit After Tax (PAT): Reported at ₹7.76 crore in Sept 2025, and ₹4.38 crore in FY23.
Net Worth: Recorded at ₹209.37 crore in Sept 2025 in comparison to ₹31.49 crore in FY23.
Reserves & Surplus: Stood at ₹188.84 crore in Sept 2025, as compared to ₹24.34 crore in FY23.
Total Borrowing: Stood at ₹76.07 crore in Sept 2025, as compared to ₹68.55 crore in FY23.
EBITDA: Stood at ₹16.24 crore in Sept 2025 in comparison to ₹17.64 crore in FY23.
The company has reported an expansion in its asset base over the reviewed period, indicating scale-up in operations and infrastructure.
Total income reflects some variation across reporting periods, suggesting changes in revenue momentum.
Profit after tax shows an improvement, indicating changes in overall profitability during the period under review.
Net worth has increased over time, reflecting changes in the company’s financial position.
Reserves and surplus have also risen, indicating accumulation of retained earnings.
Total borrowings have increased, reflecting utilisation of external funding to support operations or expansion activities.
EBITDA reflects variation across periods, indicating changes in operating performance.
Overall, the financial profile indicates developments in scale, capital structure, and operational performance, based on available data.
Variations in total income and EBITDA across reporting periods indicate changes in revenue generation and operating performance, which may reflect fluctuations in business activity.
An increase in total borrowings suggests reliance on external funding, which may have implications for financial obligations and capital structure management.
The company operates across branded generics and CDMO segments, with a diversified product portfolio spanning multiple therapeutic areas and dosage forms, indicating broad participation in the pharmaceutical formulations market.
Planned utilisation of IPO proceeds towards capacity expansion, research and development, and entry into international markets reflects initiatives aligned with operational scale and market presence.
KPI | Sept 30, 2025 | Mar 31, 2025 |
ROE | 5.13% | 16.82% |
ROCE | 9.28% | 28.92% |
RoNW | 5.09% | 15.09% |
PAT Margin | 8.93% | 8.88% |
EBITDA Margin | 18.68% | 24.18% |
Price to Book Value | 10.89 |
Registrar | Lead Manager(s) |
Bigshare Services Pvt.Ltd. | Arihant Capital Markets Ltd. |
Plot No. 39
5th floor, Lavanya Arcade Jayabheri Enclave
Gachibowli, K.V. Rangareddy, Seri Lingampally
Hyderabad, Telangana, 500032
Phone: +91 79979 91301
Email: cs@saiparenterals.com
Website: https://www.saiparenterals.com/
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Sai Parenterals IPO allotment status.
Anil Kumar Karusala is the Chairman and Managing Director of Sai Parenteral’s Ltd.
The Sai Parenteral’s IPO is scheduled to open for subscription on March 24, 2026, and will close on March 27, 2026, as per the disclosed timeline.
Sai Parenteral’s Ltd operates in the pharmaceutical formulations segment with activities across research, development, and manufacturing. Its operations include branded generic formulations and contract development and manufacturing organisation (CDMO) services for domestic and international markets. The company’s diversified product portfolio and presence across multiple therapeutic areas reflect its participation in different segments of the pharmaceutical value chain. Any assessment of long-term sustainability would depend on multiple factors, including regulatory environment, market conditions, and operational performance.
The IPO comprises 1,04,28,288 shares, aggregating up to approximately ₹409 crore, based on the disclosed issue details.
‘Pre-apply’ refers to the facility that allows investors to submit their application for an IPO before the official opening date. The application is processed once the IPO opens, in accordance with applicable procedures.
The minimum lot size for the Sai Parenteral’s IPO is 38 shares. Retail investors are required to apply for at least one lot, which represents the minimum order quantity.
The tentative allotment date for the Sai Parenteral’s IPO is March 30, 2026, based on the disclosed schedule.
The registrar for Sai Parenteral’s IPO is Bigshare Services Pvt. Ltd., as per the provided information.
There are no publicly stated governance issues or red flags highlighted. Investors may review the offer documents, including sections on management, board composition, and risk factors, for detailed and verified disclosures.
Investors can apply for the IPO through the ASBA facility using their bank account or via UPI-enabled platforms provided by trading applications. The process involves selecting the IPO, entering bid details such as quantity and price within the specified range, and authorising the payment request. The application amount remains blocked until the allotment process is completed.
Yes, a Demat account is required to apply for the IPO, as shares, if allotted, are credited in electronic form to the applicant’s Demat account.
Investors can check the allotment status once it is finalised, typically through the registrar’s website or the trading platform used for application. If shares are allotted, they are credited to the Demat account, and the status is updated accordingly.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading